Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 19, Issue 5, Pages 313-316
http://dx.doi.org/10.1155/2005/358658
Brief Communication

Demyelination-Like Syndrome In Crohn’s Disease After Infliximab Therapy

Hugh J Freeman and Borys Flak

Department of Medicine (Gastroenterology) and Department of Diagnostic Radiology, University of British Columbia, Vancouver, British Columbia, Canada

Received 8 November 2004; Accepted 2 February 2005

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [32 citations]

The following is the list of published articles that have cited the current article.

  • Sheetal B. Desai, and Daniel E. Furst, “Problems encountered during anti-tumour necrosis factor therapy,” Best Practice & Research Clinical Rheumatology, vol. 20, no. 4, pp. 757–790, 2006. View at Publisher · View at Google Scholar
  • Elena Dubcenco, Clifford A. Ottaway, Dean L. Chen, and Jeffrey P. Baker, “Neurological symptoms suggestive of demyelination in Crohn??s disease after infliximab therapy,” European Journal of Gastroenterology & Hepatology, vol. 18, no. 5, pp. 565–566, 2006. View at Publisher · View at Google Scholar
  • Laura Bernardoni, Chiara Scattolini, Luca Frulloni, and Italo Vantinipp. 157–170, 2006. View at Publisher · View at Google Scholar
  • Maria Gomez-Gallego, Andres Fernandez-Barreiro, and Jose Meca-Lallana, “Multiple sclerosis onset during etanercept treatment [6],” European Neurology, vol. 59, no. 1-2, pp. 91–93, 2007. View at Publisher · View at Google Scholar
  • Ar Bremner, and Rm Beattie, “Recent advances in the medical therapy of Crohn's disease in childhood,” Expert Opinion on Pharmacotherapy, vol. 8, no. 15, pp. 2553–2568, 2007. View at Publisher · View at Google Scholar
  • Wh Ibrahim, M Hammoudah, N Akhtar, H Al-Hail, and D Deleu, “Central Nervous System Demyelination Associated with Etanercept in a 51 Year Old Woman,” Libyan Journal of Medicine, vol. 2, no. 2, pp. 99–102, 2007. View at Publisher · View at Google Scholar
  • John C. Novak, Amy E. Lovett-Racke, and Michael K. Racke, “Monoclonal antibody therapies and neurologic disorders,” Archives of Neurology, vol. 65, no. 9, pp. 1162–1165, 2008. View at Publisher · View at Google Scholar
  • Martha E. Stokely, Puja Garg, Manzoor A. Bhat, and Peter Koulen, “Transient 5‐(4‐phenylbutoxy)psoralen (PAP‐1) treatment dissociates developing pathologies in autoimmune optic neuritis into two distinct pathology profiles,” Journal of Neuroscience Research, vol. 86, no. 9, pp. 2111–2124, 2008. View at Publisher · View at Google Scholar
  • Pedro Emilio Bermejo, and Aurora Burgos, “Complicaciones neurológicas de la enfermedad inflamatoria intestinal,” Medicina Clínica, vol. 130, no. 17, pp. 666–675, 2008. View at Publisher · View at Google Scholar
  • Nynne Nyboe Andersen, Sarah Caspersen, Tine Jess, and Pia Munkholm, “Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study,” Journal of Crohn's and Colitis, vol. 2, no. 4, pp. 304–309, 2008. View at Publisher · View at Google Scholar
  • W. Miehsler, G. Novacek, H. Wenzl, H. Vogelsang, P. Knoflach, A. Kaser, C. Dejaco, W. Petritsch, M. Kapitan, H. Maier, W. Graninger, H. Tilg, and W. Reinisch, “A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 4, no. 3, pp. 221–256, 2010. View at Publisher · View at Google Scholar
  • Marta Fernández, Xavier Montalban, and Manuel Comabella, “Orchestrating innate immune responses in multiple sclerosis: Molecular players,” Journal of Neuroimmunology, vol. 225, no. 1-2, pp. 5–12, 2010. View at Publisher · View at Google Scholar
  • Christos D. Zois, Konstantinos H. Katsanos, Maria Kosmidou, and Epameinondas V. Tsianos, “Neurologic manifestations in inflammatory bowel diseases: Current knowledge and novel insights,” Journal of Crohn's and Colitis, vol. 4, no. 2, pp. 115–124, 2010. View at Publisher · View at Google Scholar
  • Antonio G. Tristano, “Neurological adverse events associated with anti-tumor necrosis factor alpha treatment,” Journal of Neurology, vol. 257, no. 9, pp. 1421–1431, 2010. View at Publisher · View at Google Scholar
  • Finbar Maccarthy, and Laurence J. Eganpp. 360–391, 2010. View at Publisher · View at Google Scholar
  • Brian Bressler, Boulos Haraoui, Edward Keystone, and Alessandro Sette, “Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases,” Journal of Rheumatology, vol. 37, no. 85, pp. 40–52, 2010. View at Publisher · View at Google Scholar
  • Ronald F. Pfeiffer, “Neurologic Presentations of Gastrointestinal Disease,” Neurologic Clinics, vol. 28, no. 1, pp. 75–87, 2010. View at Publisher · View at Google Scholar
  • Sarah OʼDonnell, Stephen Murphy, Malik M. Anwar, Maria OʼSullivan, Niall Breslin, Humphrey J. OʼConnor, Barbara M. Ryan, and Colm A. OʼMorain, “Safety of infliximab in 10 years of clinical practice,” European Journal of Gastroenterology & Hepatology, vol. 23, no. 7, pp. 603–606, 2011. View at Publisher · View at Google Scholar
  • María Cruz Fernández-Espartero, Beatriz Pérez-Zafrilla, Antonio Naranjo, Carmen Esteban, Ana M. Ortiz, Juan J. Gómez-Reino, and Loreto Carmona, “Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review,” Seminars in Arthritis and Rheumatism, vol. 41, no. 3, pp. 524–533, 2011. View at Publisher · View at Google Scholar
  • Andrew J Solomon, Rebecca I Spain, Michael C Kruer, and Dennis Bourdette, “Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors,” Multiple Sclerosis Journal, vol. 17, no. 12, pp. 1472–1487, 2011. View at Publisher · View at Google Scholar
  • Satveer K. Mahil, Thomasin C. Andrews, Charlotte Brierley, Jonathan N. Barker, and Catherine H. Smith, “Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature,” Journal of Dermatological Treatment, vol. 24, no. 1, pp. 38–49, 2012. View at Publisher · View at Google Scholar
  • Mona M Alkhawajah, Ana B Caminero, Hugh J Freeman, and Joel JF Oger, “Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!,” Multiple Sclerosis Journal, vol. 19, no. 3, pp. 259–265, 2013. View at Publisher · View at Google Scholar
  • E. Andreadou, E. Kemanetzoglou, Ch. Brokalaki, M. E. Evangelopoulos, C. Kilidireas, A. Rombos, and E. Stamboulis, “Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature,” Case Reports in Neurological Medicine, vol. 2013, pp. 1–9, 2013. View at Publisher · View at Google Scholar
  • José M. Ferro, and Sofia Oliveira, “Neurologic Manifestations of Gastrointestinal and Liver Diseases,” Current Neurology and Neuroscience Reports, vol. 14, no. 10, 2014. View at Publisher · View at Google Scholar
  • Orly Ben-Or, Nathanel Zelnik, Ron Shaoul, Avi Pacht, and Aaron Lerner, “The Neurologic Profile of Children and Adolescents With Inflammatory Bowel Disease,” Journal of Child Neurology, vol. 30, no. 5, pp. 551–557, 2014. View at Publisher · View at Google Scholar
  • Aristeidis H Katsanos, and Konstantinos H Katsanos, “Inflammatory bowel disease and demyelination: more than just a coincidence?,” Expert Review of Clinical Immunology, vol. 10, no. 3, pp. 363–373, 2014. View at Publisher · View at Google Scholar
  • K. M. De Felice, M. Novotna, F. T. Enders, W. A. Faubion, W. J. Tremaine, O. H. Kantarci, and L. E. Raffals, “Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients,” Alimentary Pharmacology & Therapeutics, vol. 41, no. 1, pp. 99–107, 2014. View at Publisher · View at Google Scholar
  • José M. Ferro, Sofia N. Oliveira, and Luis Correia, “Neurologic manifestations of inflammatory bowel diseases,” Neurologic Aspects of Systemic Disease Part II, vol. 120, pp. 595–605, 2014. View at Publisher · View at Google Scholar
  • Su-Yin Lim, and Cris S. Constantinescu, “Neurological Complications of Anti-TNF Treatments and Other Neurological Aspects of Inflammatory Bowel Disease,” Neuro-Immuno-Gastroenterology, pp. 211–225, 2016. View at Publisher · View at Google Scholar
  • Wanis H Ibrahim, Mohammed Hammoudah, Naveed Akhtar, Hassan Al-Hail, and Dirk Deleu, “Central nervous system demyelination associated with etanercept in a 51 years old woman,” Libyan Journal of Medicine, vol. 2, no. 2, pp. 99–102, 2016. View at Publisher · View at Google Scholar
  • Melissa Shapiro, and David A. Blanco, “The Neurological Manifestations of Gastrointestinal Disease,” Seminars in Pediatric Neurology, 2017. View at Publisher · View at Google Scholar
  • David S. Posnick, Majdy AlBahhar, and Alexandra Golant, “TNF-Alpha Antagonists and Neurologic Side Effects: A Literature Review,” Psoriasis Forum, vol. 19a, no. 2, pp. 65–70, 2018. View at Publisher · View at Google Scholar